直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Spotlight on Upcoming Oral Arguments – November 2025

November 4, 2025

Authored and Edited by David L. Nielsen; Joshua A. Sprague Oliveira; Prince M. Ene, Pharm. D.; Michelle G. Rice; Erik R. Puknys

The following arguments will be available live to the public, both in-person and through online audio streaming. Access information will be available by 9 AM ET each day of argument at: https://cafc.uscourts.gov/home/oral-argument/listen-to-oral-arguments/. 


Thursday, November 6, 2025, 10:00 A.M.

Crocs, Inc. v. ITC, No. 2024-1300, Courtroom 201, Panel G

In the underlying Section 337 proceeding, Crocs alleged infringement of its 3D marks relating to the upper configuration of the classic clog. The ITC, weighing the DuPont factors for assessing a likelihood of confusion, found that Crocs failed to show the participating respondents infringed the 3D marks. The ITC thus found no Section 337 violation by the participating respondents and denied Croc’s request for a general exclusion order but did issue a limited exclusion order against the defaulting respondents. Crocs appealed.

On appeal, the parties dispute whether Crocs’ appeal was timely. Crocs filed its notice of appeal after the presidential review period and more than 60 days after the ITC issued its final determination. The ITC contends that the 60-day appeal period began when it issued the final determination and Crocs failed to appeal within that period, so the appeal should be dismissed as untimely. According to the ITC, its no-violation determination and refusal to issue a general exclusion order were final and appealable on the day they were issued. Crocs counters that the ITC determination, as a whole, was not final until the presidential review period ended.

On the merits, Crocs contends that the ITC erred in assessing the DuPont likelihood-of-confusion factors to find non-infringement. Among other errors, Crocs argues that the ITC failed to give sufficient weight to factors showing confusion and that it erred in giving dispositive weight to a control survey that improperly incorporated aspects of the 3D marks into the control. The ITC, in response, argues that the non-infringement determination should be affirmed even if the appeal were allowed to proceed. The ITC emphasizes that Crocs’ 3D marks at issue are narrowly limited to the specific patterns of holes and textured strips, not the overall clog design or other unprotected elements. The ITC contends that the determination below took that into account in evaluating the DuPont factors and that the likelihood-of-confusion evidence presented by Crocs wrongly focused on the overall look of the clog including unprotected elements.

Additionally, Crocs challenges the ITC’s refusal to issue a general exclusion order based on the violation by the defaulting respondents. The ITC counters that, because Crocs did not prove violation under the applicable evidentiary standard to support a general exclusion order, Crocs is not entitled to one.

Thursday, November 6, 2025, 10:00 A.M.

Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited, No. 2024-1606, Courtroom 201, Panel G

Torrent filed an Abbreviated New Drug Application to market a generic version of Supernus’ Trokendi XR® product, a topiramate drug used to treat epilepsy and migraines. Supernus sued Torrent for infringing its U.S. Pat. Nos. 8,992,989, 9,549,940, and 9,622,983, related to extended-release formulations of topiramate. The district court found the asserted patents not invalid but infringed under the doctrine of equivalents (“DOE”). In reaching its infringement determination, the court rejected Torrent’s prosecution-history-estoppel argument.

During prosecution of a related patent, to overcome the Examiner’s written-description rejection under § 112, Supernus amended its claims to recite formulations comprising a coating “selected from the group consisting of cellulosic polymers and acrylic polymers.” Torrent argued that this narrowing amendment disclaimed formulations with other coating materials such as the alleged equivalent at issue, polyvinyl acetate (a vinyl polymer). The district court, however, found that the presumption of prosecution history estoppel was rebutted because the amendment was only tangentially related to the alleged equivalent. The court thus held that Torrent infringed under the DOE. Torrent appealed.

On appeal, among other arguments, Torrent takes issue with the district court’s application of the tangential-relation exception. According to Torrent, this exception applies only where the reason for the claim amendment bears no more than “a tangential relationship” to the alleged equivalent. Here, continues Torrent, the only objectively apparent reason for Supernus’ amendment was to “disclaim coverage of any other coating materials containing polymers other than cellulosic and acrylic polymers.” This reason, according to Torrent, bears a direct, not tangential, relation to the vinyl-polymer equivalent at issue and therefore precludes application of the exception. Torrent thus contends that prosecution history estoppel should have barred Supernus’ assertion of infringement under the DOE.

In response, Supernus argues that the district court properly found only a tangential relation between the amendment in question and the alleged equivalent. According to Supernus, the amendment addressed the Examiner’s § 112 rejection and was not intended to exclude the alleged equivalent here. Supernus also argues, in the alternative, that prosecution history estoppel does not apply because the amendment was made during the prosecution of an unasserted patent, and the amended term does not appear in the asserted claims.

Monday, November 10, 2025, 10:00 A.M.

Micron Technology Inc. v. Longhorn IP LLC, No. 2023-2007, Courtroom 201, Panel K

This appeal stems from a district court order requiring patent-assertion entities to post a bond under a state bad-faith-assertion law before proceeding with their patent infringement suit. Under Idaho’s Bad Faith Assertions of Patent Infringement Act (“BFA” Act), a court may order a bond if a defendant shows that a plaintiff’s infringement assertions are made in bad faith. After a Longhorn affiliate and patent-assertion entity sued Micron for patent infringement, Micron raised a BFA counterclaim and sued Longhorn in state court with a bond motion. The state court case was later removed to the Idaho district court, which presided over both cases. The district court denied the Longhorn entities’ motion to dismiss Micron’s BFA claim. The court also granted Micro’s bond motion, requiring Longhorn to post an $8 million bond before proceeding with its infringement claims. Longhorn appealed.

On appeal, Longhorn raises both as-applied and facial challenges to the BFA Act. For its as-applied challenge, Longhorn contends that Micron’s BFA claim should have been dismissed because Micron failed to demonstrate that Longhorn’s patent infringement assertions were objectively baseless. Longhorn also contends that the Act is facially unconstitutional and preempted by federal law. According to Longhorn, the Act ignores that patent infringement assertions are presumed to be made in good faith and that the Act distorts the balance of rights in patent litigation. Relatedly, Longhorn contends that the district court wrongly and unconstitutionally ordered a coercive bond under the Act to punish it for enforcing its patents.

In response, Micron argues that the appeal should be dismissed because the bond order is not an injunction-like order qualifying for an interlocutory appeal and is not an appealable collateral order. Further, Micron argues that even if the appeal were proper, Longhorn’s challenges to the BFA Act fail. Specifically, Micron contends that it pleaded detailed factual assertions to demonstrate objective bad faith under the BFA Act, and that patent law does not preempt state law tort claims based on bad-faith patent assertions. Further, Micron argues that the district court properly applied the Act to order the bond.

This case presents the first appeal to the Federal Circuit challenging a bond order under state law. The court’s decision may address how state-law bond requirements impact patent infringement suits involving patent assertion entities.

Tags

International Trade Commission (ITC), likelihood of confusion, Doctrine of Equivalents, Written description (35 USC § 112), patent infringement

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Diligence, Licensing, and Opinions

Global IP Enforcement, Litigation, and Trials

Trademark Litigation and Trials

Branded Hatch-Waxman (ANDA) Litigation and Trials

Prosecution and Portfolio Management

Trademark and Brand Management

Related Industries

AI, Electronics, and Information Technology

Chemicals, Industrials, and Materials

Textiles

Manufacturing

Consumer Goods and Services

Life Sciences

Pharmaceutical

Related Offices

Atlanta, GA

Palo Alto, CA

Washington, DC

Contacts

David L. Nielsen
Associate
Atlanta, GA
+1 404 653 6443
Email
Joshua A. Sprague Oliveira
Associate
Washington, DC
+1 202 408 4487
Email
Prince M. Ene, Pharm. D.
Associate
Washington, DC
+1 202 408 4036
Email
Michelle_Yongyuan_Rice
Michelle G. Rice
Associate
Washington, DC
+1 202 408 4229
Email
Erik R. Puknys
Partner
Palo Alto, CA
+1 650 849 6644
Email

Copyright © 2025 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Articles

COPPA’s Amended Rule Is Now in Full Effect: What Operators Need to Know

May 15, 2026

INCONTESTABLE® Blog

Netflix Prevails in Copyright Infringement Suit Regarding Tiger King

May 14, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP